Articles tagged with Lung Cancer
A new study by researchers at the University of Michigan Comprehensive Cancer Center found that higher doses of radiation combined with chemotherapy improve survival in patients with stage III lung cancer. Concurrent chemotherapy increases treatment effectiveness and overall survival rates.
A retrospective analysis found that multiple lung tumors in patients often arise from a single cancer cell, suggesting multifocal lung cancers should be classified as advanced-stage cancers. The study analyzed 70 tumor samples and concluded that 77% of patients had multiple tumors originating from a single clone.
A large cohort study found that long-term survivors of hereditary retinoblastoma are at a significantly increased risk of death due to subsequent cancers. Hereditary retinoblastoma survivors had a 35-fold higher mortality rate compared to the general population.
Researchers at UVA Health System found that SRC gene promotes growth suppression in bladder cancer, contradicting its role in most cancers. The study suggests caution when using targeted therapeutic agents that inhibit SRC in bladder cancer treatment.
Researchers found that cetuximab's success in treating non-small cell lung cancer depends on the production of a specific protein called u-PAR. Higher levels of u-PAR indicate reduced responsiveness to the treatment, suggesting it could be used as a biomarker.
A new technique called stereotactic body radiotherapy (SBRT) has been shown to significantly improve survival rates for early-stage lung cancer patients, with a median survival range of over 32 months. The treatment doubles the odds of surviving and can even cure at least half of the patients, offering hope without the need for surgery.
A recent study found that socioeconomic status is linked to an increased risk of developing lung cancer, with Europeans having lower education levels experiencing a higher incidence. The research suggests that while smoking accounts for approximately half of this risk, diet and other factors also play a role in the disparity.
Researchers at Wake Forest University have developed a new class of platinum-based anti-tumor drugs that demonstrate 10 times greater efficacy than current treatments against certain lung cancer types. The compounds work by rapidly binding with and disabling tumor cell DNA, potentially overcoming drug resistance issues.
Survivors of early-stage lung cancer who engage in regular physical activity experience improved mood, vigor, and physical functioning. Moderate exercise, such as brisk walking a few times a week, may promote better quality of life and reduce depressive symptoms.
The 2009 awards recognize groundbreaking work in early detection of ovarian and lung cancers, improvements to bone marrow transplant safety, and discovery of new genetic markers for cancer. The $450,000 prize will support the projects over three years.
A recent UC Davis study found that smoking is linked to over 70% of cancer death burden among Massachusetts men in 2003, surpassing previous estimates. The study suggests that increased tobacco control efforts could save more lives and improve health outcomes.
A study examines racial disparities in survival among black patients diagnosed with early-stage lung cancer. Despite recommended treatment, black patients have lower five-year survival rates compared to white patients.
The National Lung Cancer Partnership and LUNGevity Foundation have awarded $100,000 research grants to Prasad Adusumilli and Lee Goodglick. Dr. Adusumilli's study will investigate visceral pleural invasion, while Dr. Goodglick's research focuses on estrogen's role in lung cancer.
National Lung Cancer Partnership awards I-Ching Wang a Career Development Award to study FoxM1, a protein linked to aggressive lung cancer growth. The grant aims to support protein-directed therapies and control the leading US cancer killer. Dr. Wang's research will help combat underfunding in federal lung cancer research.
A recent study by Boston University researchers has identified a class of microRNAs that regulate gene expression changes in airway cells caused by smoking and lung cancer. These findings may lead to a non-invasive biomarker for smoking-related lung diseases, improving early diagnosis and treatment options.
Researchers at the University of Cincinnati have identified a new tumor suppressor, protein kinase C-zeta, that may help develop targeted drug therapies to combat lung cancer. The study found that PKC-zeta normally slows down Ras transformation and prevents tumor development, but its absence or inactivity accelerates cancer growth.
Researchers found that silencing of a crucial gene in lung cancer leads to impairment in genome-wide changes, contributing to cancer development and progression. Tobacco use is strongly linked to modification of the MTHFR gene, which triggers global hypomethylation and deregulation of DNA synthesis.
A research team at UC San Diego has identified a protein called versican that enhances metastasis by stimulating inflammatory cells. Versican is found in low amounts in normal lung epithelial cells but is upregulated in aggressive lung tumors, supporting the growth and spread of cancer.
Research suggests that high intake of inorganic phosphates, found in processed foods, can stimulate lung cancer development and growth. Dietary regulation of phosphates may play a critical role in treatment and prevention of the disease.
Research identified common variants in ABCB1 and ABCC1 genes that increase lung cancer risk. Variants were found more often in patients than controls, particularly in women and younger individuals. These findings may help prevent tobacco-related cancers.
Researchers have identified a gene mutation in SFTPA2 that is linked to an inherited form of idiopathic pulmonary fibrosis, a lethal lung disease affecting older adults. The same mutation is also associated with lung cancer.
Researchers at University of Nottingham identified the tumour suppressor gene LIMD1 as a protector against lung cancer. The study found that LIMD1 was missing in majority of lung cancer samples, indicating its protective role. This breakthrough could lead to early screening techniques and treatments for lung cancer.
Researchers found that combining PI3K and MEK inhibitors led to significant tumor shrinkage in mice with lung cancer driven by K-Ras mutations. The combination treatment eradicated the tumors with minimal toxicity, providing a strong rationale for testing this therapy in human trials.
The report found declines in both cancer incidence and death rates, as well as wide variations in lung cancer trends from state to state. Tobacco control measures are key to reducing the risk of lung cancer.
The report reveals declines in cancer incidence and death rates across the US, with some states experiencing significant variations in lung cancer trends. These findings underscore the need to strengthen tobacco control programs and accelerate efforts to prevent or reduce the occurrence of kidney and liver cancers.
A team of researchers found that a tiny protein called alpha-catenin is essential for forming strong bonds between cells. Cancer cells with dysfunctional alpha-catenin can break free and spread the disease, but scientists may be able to develop therapies to repair or replace this protein and prevent cancer's progression.
According to a recent report, cancer incidence and mortality have declined in the US for the first time among both men and women. The decline is attributed to decreases in the most common cancers, including prostate, lung, and colorectal cancer.
The INTEREST study found oral gefitinib comparable to injected docetaxel in non-small cell lung cancer patients, with better quality of life. Common side effects included rash and diarrhoea with gefitinib, while neutropenia and asthenic disorders were more common with docetaxel.
A study published by the American Association for Cancer Research found that cruciferous vegetables like broccoli may lower lung cancer risk in smokers. The study showed a significant protective effect, with risks ranging from 20% to 55% depending on the type and duration of smoking.
Researchers studied DNA methylation in former smokers and found differences between those with lung cancer and disease-free individuals. Altered methylation levels may explain why some former smokers develop lung cancer despite quitting smoking.
A phase III clinical trial found that adding bevacizumab to erlotinib therapy improves progression-free survival in advanced non-small cell lung cancer patients, but not overall survival. The combination also shows a response rate and tumor shrinkage.
A multi-center phase II clinical trial found improved survival in patients with advanced non-small cell lung cancer treated with chemotherapy and targeted therapies bevacizumab and cetuximab. The combination showed no safety concerns, indicating a potential future treatment option for lung cancer.
Researchers found that proton therapy with concurrent chemotherapy significantly reduced bone marrow toxicity in patients with locally advanced non-small cell lung cancer, improving treatment efficacy and patient outcomes. The study suggests proton therapy as a safer option for vulnerable patients, including children and the elderly.
A study led by The University of Texas M. D. Anderson Cancer Center has found a four-drug regimen of carboplatin, paclitaxel, bevacizumab, and cetuximab to be safe for patients with advanced lung cancer. The regimen showed modest improvement in survival rate, with 53% of patients experiencing tumor shrinkage.
A study found that African-American patients with non-small cell lung cancer have a higher copy number of the epidermal growth factor receptor (EGFR) gene, predicting better long-term outcomes when taking erlotinib and gefitinib. Few EGFR mutations were observed, highlighting the need for more research in this patient population.
A recent study published by the American Society for Radiation Oncology found that males diagnosed with non-small cell lung cancer have a higher mortality rate than females. The research also revealed that gender is a significant prognostic factor in lung cancer patients' overall survival rates.
A new Cornell study found a strong relationship between allergies and cancer in tissues exposed to environmental factors, such as eczema, hives, and hay fever. Allergies linked to these conditions were most strongly associated with lower rates of cancers in exposed tissues.
Researchers found that allergy symptoms may protect against cancer by removing foreign particles and substances from organs that come into contact with them. However, the relationship between asthma and lung cancer is a special case where asthma actually increases lung cancer rates.
New report finds lung cancer media coverage is on the rise, but with a significant decrease in positive coverage and an overemphasis on smoking as a risk factor. Despite this, breast cancer coverage remains more favorable, often featuring personal stories of survivors.
A study by Stanford Cancer Center found that younger patients (15-39 years) with lung cancer exhibit better survival rates and distinct clinical features compared to older patients. The age-adjusted incidence rate of lung cancer in younger patients was significantly lower, and they had a higher proportion of distant disease at diagnosis.
Researchers found that video-assisted thoracic surgery (VATS) for stage I non-small cell lung cancer results in shorter post-operative hospital stays and faster removal of chest tubes compared to traditional open surgery. The study also showed comparable outcomes in terms of surgical success and complication rates.
Research found skewed X inactivation in women with BRCA1 gene mutations, associated with a later onset of breast or ovarian cancer. The Impact of Cancer scale was also refined and validated, providing a tool to measure long-term psychosocial impact on cancer survivors.
Researchers found that in-home photography may be a cost-effective alternative to professional visual home assessments for identifying asthma triggers. Additionally, health-care utilization for children with asthma peaks in the fall, while tadalafil shows promise as an effective therapy for pulmonary hypertension. In-hospital statin us...
Researchers have discovered 26 new genes linked to lung adenocarcinoma, a type of non-small cell lung cancer. The study's findings suggest that these genetic alterations can be targeted with specific treatments, offering new hope for patients.
A study of 188 patients revealed 26 genes involved in the development of lung adenocarcinoma and its sub-types, including those in non-smokers. The findings could lead to improved diagnosis and treatment options for this deadliest form of lung cancer.
A collaborative study of nearly 200 lung cancer patients has identified over 1,000 genetic alterations and pinpointed 26 frequently altered genes. The research highlights the importance of integrating multiple large-scale approaches to highlight key molecular defects in lung tumors.
A Harvard T.H. Chan School of Public Health study projects that China will experience an estimated 65 million COPD deaths and 18 million lung cancer deaths between 2003 and 2033 if current smoking and biomass fuel use levels continue, highlighting the need for large-scale interventions to reduce disease burden
A study finds that eliminating smoking and solid fuel use in China could prevent millions of deaths from chronic diseases. Gradual elimination or moderate-aggressive interventions could avoid 26-31 million COPD deaths and 6.3 million lung cancer deaths by 2033.
Scientists identified P-Cadherin as a key molecule in causing colon cancer, with abnormal expression leading to pre-cancerous growths in the bowel. Their findings hold promise for preventative therapies and lifestyle changes to prevent or treat the disease.
A study analyzing English cancer patients found that cervical and lung cancer rates are higher among poor people, while breast and melanoma rates are higher in wealthier groups. Smoking is strongly associated with socioeconomic status and contributes to the higher incidence of lung cancer in deprived groups.
A study published in the Archives of Internal Medicine found that physicians rarely responded empathically to patients' concerns about mortality, symptoms, or treatment options. The researchers identified 384 moments of
A study of 20 recorded interactions found that physicians rarely responded empathetically to concerns raised by patients with lung cancer. Opportunities for empathy were most often related to the impact of lung cancer on patients' morbidity and mortality expectations, but were frequently overlooked by physicians.
Multidisciplinary approaches combining chemotherapy, radiotherapy, and surgery have shown promise in treating various cancers, including lung and head and neck cancers. The addition of targeted therapies like pazopanib and cetuximab has demonstrated significant activity in reducing tumor size and improving patient outcomes.
In a phase II trial, pazopanib was found to shrink lung cancer tumors in 30 out of 35 patients by up to 85%. The results suggest that pazopanib is highly active in early stage operable lung cancer. Further development of this drug in lung cancer is underway.
A new blood test uses immune system signals to detect early signs of lung cancer, signaling the disease before symptoms appear. The test has a sensitivity rate of 51% and specificity rate of 18%, indicating its potential for improving early detection of lung cancer.
A study at ESMO found gefitinib to be more tolerable and result in a greater likelihood of response in non-smoking Asian patients with adenocarcinoma of the lung. The targeted therapy is now considered a first-line treatment for this population.
Researchers found that patients with specific EGFR gene mutations can live almost two years on average when treated with erlotinib, outperforming chemotherapy by two-to-three fold. The study identified a subgroup of 15-22% patients who can benefit from targeted therapies
A narrow genetic region on chromosome 15 has been found to significantly increase the risk of familial lung cancer by 5.7- to 7.2-fold, regardless of smoking status. The study identified specific genetic variants associated with the increased risk and suggests they may be targeted for cancer therapies.
A study adjusting for a known bias in familial melanoma risk estimates reveals an increased relative risk of 3.18, with higher risks for young-onset cases. In contrast, the risks for colorectal, lung, breast, and prostate cancer remain relatively stable.
A new study by the American Cancer Society found that lung cancer death rates among never-smokers are highest among men, African Americans, and Asians in Asia. The review analyzed data from over 630,000 individuals and found that the incidence of lung cancer among lifelong nonsmokers is similar to brain and nervous system cancers.